- Home
- CELU vs MBRX Comparison
CELU vs MBRX Comparison
Compare CELU & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELU | MBRX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 16.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CELU | MBRX |
|---|---|---|
| Price | $0.76 | $2.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $61.00 |
| AVG Volume (30 Days) | 80.7K | ★ 279.8K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.26 |
| 52 Week High | $4.30 | $7.98 |
Technical Indicators
Market Signals| Indicator | CELU | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 42.85 |
| Support Level | $0.69 | $2.00 |
| Resistance Level | $0.85 | $2.58 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 19.40 | 33.71 |
Price Performance
Historical ComparisonAbout CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.